打开主菜单

罗非昔布罗非考昔(英語:Rofecoxib/ˌrɒfˈkɒksɪb/)商品名VioxxCeoxxCeeoxx。是一种非甾体类抗炎药NSAID),由默克公司製造、出售。美国食品药品监督管理局(FDA)于1999年5月20日批准上市,用以治疗骨关节炎急性疼痛痛经

罗非昔布
Rofecoxib.svg
Rofecoxib-3D.png
系统(IUPAC)命名名称
4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one
临床数据
妊娠分级
  • AU: C
给药途径 oral
合法狀態
合法状态
药代动力学数据
生物利用度 93%
蛋白结合度 87%
代谢 hepatic
生物半衰期 17 hours
排泄 biliary/renal
识别信息
CAS注册号162011-90-7 ✓
ATC代码 M01AH02
PubChem CID 5090
DrugBank DB00533 ✓
ChemSpider 4911 ✓
UNII 0QTW8Z7MCR ✓
KEGG D00568 ✓
ChEBI CHEBI:8887 ✓
ChEMBL英语ChEMBL CHEMBL122 ✓
化学信息
化学式 C17H14O4S
摩尔质量 314.357 g/mol
  (verify)

由於發現到長期且高劑量用藥有增加心臟病的風險[1][2],默克公司於2004年9月30日起從市場撤回此藥。

合成编辑

 
罗非昔布的合成[3]

注脚编辑

参考文献编辑

  • FDA (2005). "Summary minutes for the February 16, 17 and 18, 2005, Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee." Published on the internet, March 2005. Link
  • Fitzgerald GA, Coxibs and Cardiovascular Disease, N Engl J Med 2004;351(17): 1709–1711. PMID 15470192.
  • Grassley CE (15 Oct 2004). Grassley questions Merck about communication with the FDA on Vioxx. Press Release.
  • Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (published online; see also Merck response below)
  • Karha J and Topol EJ. The sad story of Vioxx, and what we should learn from it Cleve Clin J Med 2004; 71(12):933-939. PMID 15641522
  • Michaels, D. (June 2005) DOUBT Is Their Product, Scientific American, 292 (6).
  • Merck & Co., (5 Nov 2004). Response to Article by Juni et al. Published in The Lancet on Nov. 5. Press Release.
  • Merck & Co (30 Sep 2004) Merck Announces Voluntary Worldwide Withdrawal of VIOXX. Press release [1].
  • D. M. Mukherjee, S. E. Nissen, and E. J. Topol, "Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors," Journal of the American Medical Association 186 (2001): 954–959.
  • Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352(11):1081-91. PMID 15713945
  • Okie, S (2005) "Raising the safety bar--the FDA's coxib meeting." N Engl J Med. 2005 Mar 31;352(13):1283-5. PMID 15800221.
  • Leleti Rajender Reddy, Corey EJ. Facile air oxidation of the conjugate base of rofecoxib (Vioxx), a possible contributor to chronic human toxicity Tetrahedron Lett 2005, 46: 927. doi:10.1016/j.tetlet.2004.12.055
  • Swan SK et al., Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet. Annals of Int Med 2000; 133:1–9
  • Targum, SL. (1 Feb. 2001) Review of cardiovascular safety database. FDA memorandum. [2]
  • Wolfe, MM et al., Gastrointestinal Toxicity of Nonsteroidal Anti-anflamattory Drugs, New England Journal of Medicine. 1999; 340; 1888-98.

外部链接编辑